- Home
- STEC vs FEMY Comparison
STEC vs FEMY Comparison
Compare STEC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- FEMY
- Stock Information
- Founded
- STEC 2006
- FEMY 2004
- Country
- STEC Hong Kong
- FEMY United States
- Employees
- STEC N/A
- FEMY N/A
- Industry
- STEC
- FEMY Medical/Dental Instruments
- Sector
- STEC
- FEMY Health Care
- Exchange
- STEC NYSE
- FEMY Nasdaq
- Market Cap
- STEC 63.8M
- FEMY 29.9M
- IPO Year
- STEC 2021
- FEMY 2021
- Fundamental
- Price
- STEC $0.74
- FEMY $0.83
- Analyst Decision
- STEC
- FEMY Strong Buy
- Analyst Count
- STEC 0
- FEMY 3
- Target Price
- STEC N/A
- FEMY $8.67
- AVG Volume (30 Days)
- STEC 12.8K
- FEMY 158.0K
- Earning Date
- STEC 08-05-2025
- FEMY 08-07-2025
- Dividend Yield
- STEC N/A
- FEMY N/A
- EPS Growth
- STEC N/A
- FEMY N/A
- EPS
- STEC N/A
- FEMY N/A
- Revenue
- STEC $10,672,000.00
- FEMY $1,699,232.00
- Revenue This Year
- STEC $9,392.20
- FEMY $283.83
- Revenue Next Year
- STEC N/A
- FEMY $161.03
- P/E Ratio
- STEC N/A
- FEMY N/A
- Revenue Growth
- STEC N/A
- FEMY 61.97
- 52 Week Low
- STEC $0.20
- FEMY $0.69
- 52 Week High
- STEC $3.25
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- STEC 38.03
- FEMY 37.62
- Support Level
- STEC $0.70
- FEMY $0.91
- Resistance Level
- STEC $0.80
- FEMY $0.93
- Average True Range (ATR)
- STEC 0.08
- FEMY 0.04
- MACD
- STEC 0.00
- FEMY -0.01
- Stochastic Oscillator
- STEC 34.03
- FEMY 5.12
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.